Gregory S. Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune. Prior to Evommune, Greg served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon’s successful $1.9 billion acquisition in 2021. Greg helped lead Kadmon’s integration into Sanofi, with broad corporate oversight over legal, compliance, business development, alliance management, human resources, quality assurance, and CMC business functions. During his decade-long tenure at Kadmon, Greg served in various roles of increasing responsibility. He was a key strategic partner in financing activities, including the transition from a private to a public company, helping raise more than a billion dollars in debt and equity, and business development efforts, including the spin-off of its gene therapy platform, various international and domestic collaboration and license, co-promotion and distribution agreements, and joint ventures. Greg also helped establish, and then led, Kadmon’s corporate governance, public company, and healthcare compliance programs. Prior to joining Kadmon in 2012, Greg served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes.
Greg currently serves on the board of Vitls, Inc. Greg earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia.